Pharmacotherapy in sickle cell disease—state of the art and future prospects. （開啟新視窗）

Hankins J, Aygun B.

出處‎: Br J Haematol 2009;145(3):296-308.

檢索‎: PubMed 19222472

DOI碼‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 （開啟新視窗）

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. （開啟新視窗）

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

出處‎: Blood 2005;106(7):2269-75.

檢索‎: PubMed 16172253

DOI碼‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 （開啟新視窗）

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. （開啟新視窗）

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

出處‎: N Engl J Med 2020;382(26):2524-33.

檢索‎: PubMed 32579813

DOI碼‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 （開啟新視窗）

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. （開啟新視窗）

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

出處‎: Br J Haematol 2013;161(6):852-60.

檢索‎: PubMed 23590693

DOI碼‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 （開啟新視窗）

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. （開啟新視窗）

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

出處‎: Arch Dis Child 2013;98(11):908-14.

檢索‎: PubMed 23995076

DOI碼‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 （開啟新視窗）

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. （開啟新視窗）

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

出處‎: Pediatrics 2008;122(6):1332-42.

檢索‎: PubMed 19047254

DOI碼‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 （開啟新視窗）

Impact of hydroxyurea on clinical events in the BABY HUG trial. （開啟新視窗）

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

出處‎: Blood 2012;120(22):4304-10.

檢索‎: PubMed 22915643

DOI碼‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 （開啟新視窗）

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. （開啟新視窗）

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

出處‎: N Engl J Med 2019;380(2):121-31.

檢索‎: PubMed 30501550

DOI碼‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 （開啟新視窗）

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. （開啟新視窗）

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

出處‎: J Pediatr 2002;140(2):225-9.

檢索‎: PubMed 11865275

DOI碼‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 （開啟新視窗）

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. （開啟新視窗）

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

出處‎: Pediatrics 2013;132(4):677-83.

檢索‎: PubMed 23999955

DOI碼‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 （開啟新視窗）

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). （開啟新視窗）

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

出處‎: Lancet 2011;377(9778):1663-72.

檢索‎: PubMed 21571150

DOI碼‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 （開啟新視窗）

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. （開啟新視窗）

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

出處‎: Lancet 2016;387(10019):661-70.

檢索‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 （開啟新視窗）

How I use hydroxyurea to treat young patients with sickle cell anemia. （開啟新視窗）

Ware RE.

出處‎: Blood 2010;115(26):5300-11.

檢索‎: PubMed 20223921

DOI碼‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 （開啟新視窗）

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. （開啟新視窗）

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

出處‎: Blood 2004;103(6):2039-45.

檢索‎: PubMed 14630791

DOI碼‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 （開啟新視窗）

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. （開啟新視窗）

Hirst C, Owusu-Ofori S.

出處‎: Cochrane Database Syst Rev 2012;(9):CD003427.

檢索‎: PubMed 22972063

DOI碼‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 （開啟新視窗）

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. （開啟新視窗）

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

出處‎: Lancet Haematol 2021;8(5):e323-33.

檢索‎: PubMed 33838113

DOI碼‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 （開啟新視窗）

Sickle cell disease. （開啟新視窗）

Meremikwu MM, Okomo U.

出處‎: BMJ Clin Evid 2011;02:2402.

檢索‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 （開啟新視窗）

A phase 3 trial of l-glutamine in sickle cell disease. （開啟新視窗）

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

出處‎: N Engl J Med 2018;379(3):226-35.

檢索‎: PubMed 30021096

DOI碼‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 （開啟新視窗）

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. （開啟新視窗）

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

出處‎: Blood. 2023 23;141(12):1402-10.

檢索‎: PubMed 36375125

DOI碼‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ （開啟新視窗）

Malaria chemoprophylaxis in sickle cell disease. （開啟新視窗）

Oniyangi O, Omari AA.

出處‎: Cochrane Database Syst Rev 2006;(4):CD003489.

檢索‎: PubMed 17054173

DOI碼‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 （開啟新視窗）